Welcome to today’s podcast, covering American College of Cardiology Scientific Sessions & Expo. From 6–8 April 2024, in Atlanta, Georgia, over 17,000 cardiovascular professionals from around the globe came together to debate and discuss practice-changing science and innovations. Today, I was able to interview 2 of the late-breaking trialists.
Firstly, we speak with Prof. Gregg Stone, MD, a professor of cardiology and population health sciences at Icahn School of Medicine at Mount Sinai, opened the festivities by presenting findings from RELIEVE-HF, a randomised trial designed to evaluate the safety and effectiveness of treating heart failure patients with an interatrial shunt. Prof. Stone and colleagues randomised more than 500 patients in North America, Europe, Israel, Australia, and New Zeeland to either receive the V-Wave Ventura Interatrial Shunt System—a small device designed to reduce pressure on the left atrium and the lungs—or undergo a placebo procedure. The results are clear, and keep listening to hear his interpretation of the results.
Next, we speak with Prof. Javed Butler, MD, president of the Baylor Scott and White Research Institute, who presented results from the EMPACT-MI randomised trial, which examined treating patients with empagliflozin following a heart attack. Treatment with empagliflozin did not significantly impact the study’s primary endpoint—the combination of heart failure hospitalisations and all-cause mortality—but it did appear to dramatically improve heart failure hospitalisation rates when tracked on their own. These results add to our understanding of SGLT2 inhibitors and contribute to the body of evidence across 6 clinical studies examining the potential for empagliflozin to impact major outcomes in a broad population of adults with heart failure, chronic kidney disease or type 2 diabetes.
Enjoy listening!
Posted on
Previous Article
« Second-line therapy for multiple myeloma: Where we are now? Next Article
New atrial fibrillation associated with a high risk of major cardiovascular outcomes »
« Second-line therapy for multiple myeloma: Where we are now? Next Article
New atrial fibrillation associated with a high risk of major cardiovascular outcomes »
Table of Contents: ACC 2024
Featured articles
Matters of the heart: late-breaking news from the American College of Cardiology
Heart Failure and Cardiomyopathy
STEP-HFpEF DM: Semaglutide beneficial in patients with HFpEF and diabetes
IMPROVE-HCM: Promising results for ninerafaxstat in non-obstructive HCM
Acute Coronary Syndrome and Acute Myocardial Infarction
ACS: Necessary DAPT after PCI may be shorter than currently advised
AEGIS-II: ApoA-1 did not reduce MACE in patients with myocardial infarction but may provide benefit in patients with high LDL levels
REDUCE-AMI: Re-evaluating the role of routine beta-blockade in patients with acute myocardial infarction
Interventional Cardiology in 2024
Self-expanding versus balloon-expendable TAVR in patients with small aortic annuli
Safety of TAVI non-inferior to SAVR for patients with lower surgical risk
Interatrial shunt for HF: neutral primary endpoint but potential benefit in HFrEF
Peripheral artery disease: procedure-guidance by IVUS superior to angiography
IVUS-guided PCI beats angiography in patients with acute coronary syndrome
Addressing frailty in patients undergoing TAVR
Novel Developments in Risk Factor Management
Preventive PCI of vulnerable intracoronary plaque leads to favourable outcomes
KARDIA-2: Add-on zilebesiran effectively lowers blood pressure
BRIDGE-TIMI 73a: Olezarsen halves triglyceride levels
Plozasiran: A novel approach to severe hypertriglyceridaemia
High-risk and very high-risk patients meet LDL-cholesterol targets with lerodalcibep
No cardioprotective effect of ACE inhibitors in patients with cancer
Best of Posters
SGLT2 inhibition in heart failure more advantageous for women than men
Anxiety and depression: Lifestyle influential in MACE prevention
Meet the Trialists
Related Articles
August 26, 2022
Signs of heart disease may be more subtle in women than in men
October 30, 2023
Catheter ablation saves lives in end-stage HF with AF
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com